Autolus Therapeutics plc (FRA:6A3A)

Autolus Therapeutics Statistics

Total Valuation

FRA:6A3A has a market cap or net worth of EUR 315.93 million. The enterprise value is 279.60 million.

Market Cap	315.93M
Enterprise Value	279.60M

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+14.66%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	110.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.25
PB Ratio	1.40
P/TBV Ratio	1.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.46
EV / Sales	6.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.15

Financial Position

The company has a current ratio of 6.19, with a Debt / Equity ratio of 1.23.

Current Ratio	6.19
Quick Ratio	5.52
Debt / Equity	1.23
Debt / EBITDA	n/a
Debt / FCF	-1.14
Interest Coverage	-24.04

Financial Efficiency

Return on equity (ROE) is -60.56% and return on invested capital (ROIC) is -25.02%.

Return on Equity (ROE)	-60.56%
Return on Assets (ROA)	-22.99%
Return on Invested Capital (ROIC)	-25.02%
Return on Capital Employed (ROCE)	-47.32%
Revenue Per Employee	67,144
Profits Per Employee	-295,221
Employee Count	650
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:6A3A has paid 3.94 million in taxes.

Income Tax	3.94M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.90% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-58.90%
50-Day Moving Average	1.28
200-Day Moving Average	1.52
Relative Strength Index (RSI)	49.63
Average Volume (20 Days)	307

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.91

Income Statement

In the last 12 months, FRA:6A3A had revenue of EUR 43.58 million and -191.60 million in losses. Loss per share was -0.72.

Revenue	43.58M
Gross Profit	-115.39M
Operating Income	-233.48M
Pretax Income	-187.66M
Net Income	-191.60M
EBITDA	-225.59M
EBIT	-233.48M
Loss Per Share	-0.72

Balance Sheet

The company has 313.15 million in cash and 277.15 million in debt, giving a net cash position of 36.00 million.

Cash & Cash Equivalents	313.15M
Total Debt	277.15M
Net Cash	36.00M
Net Cash Per Share	n/a
Equity (Book Value)	226.24M
Book Value Per Share	0.85
Working Capital	367.77M

Cash Flow

In the last 12 months, operating cash flow was -216.64 million and capital expenditures -26.46 million, giving a free cash flow of -243.09 million.

Operating Cash Flow	-216.64M
Capital Expenditures	-26.46M
Free Cash Flow	-243.09M
FCF Per Share	n/a

Margins

Gross Margin	-264.79%
Operating Margin	-535.79%
Pretax Margin	-430.65%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:6A3A does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.66%
Shareholder Yield	-14.66%
Earnings Yield	-60.65%
FCF Yield	-76.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:6A3A has an Altman Z-Score of -2.34 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.34
Piotroski F-Score	2